Chiesi Ventures
Corporate VCBoston · Seed–Series A · 2 people tracked
Investment thesis
Chiesi Ventures is a corporate venture capital firm dedicated to rare and orphan diseases. It seeks to complement the strategic interests of its parent, the Chiesi Group, by backing early-stage development opportunities and treatments for rare diseases. The firm also works to broaden the Chiesi network across Europe and the United States, building relationships with universities, other venture capital investors, rare disease patient organizations, and entrepreneurial companies developing therapies in this space.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website & public directories
What they invest in
from 6 of 9 portfolio companiesBiotech ×6Healthtech ×2Medical Devices ×1
HQs:United States×7
Investments · 9 tracked
founders shown can be your intro pathBy year:2016 · 12015 · 12 dated
BiotechEmeryville, US
David Kirn(Executive Officer, Director)David Schaffer(Director)Theresa Janke(Executive Officer)
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Michael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)Peter Wirth(Director)
Rare liver disease treatment company.
San Diego, US
Chris Peetz(Founder)in
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
San Francisco, US
Board seatGiacomo Chiesi· per SEC Form D
Discovering and developing therapies for neurodegenerative diseases including Parkinson's and Alzheimer's.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)Christopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Minoryx is a biopharmaceutical company that discovers and develops drug treatments for severe orphan diseases of the central nervous system, such as cerebral adrenoleukodystrophy and Rett syndrome.
BiotechHealthtech
BiotechMedford, US
Biju Parekkadan(Director)Brian Miller(Executive Officer, Director)
BoardMartin Heidecker(Director)Greg Bailey(Director)Rich Ganz(Director)
Exits · 3
IPOs and acquisitions across the tracked portfolio4D Molecular TherapeuticsNASDAQ: FDMTAura BiosciencesNASDAQ: AURAMirum PharmaceuticalsNASDAQ: MIRM
Portfolio news
latest coverage across their companiesAura Biosciences · tickerreport.com · Aug 18, 2026
Mirum Pharmaceuticals · finance.yahoo.com · Aug 13, 2026
Frequently asked questions
- How many investments has Chiesi Ventures made?
- Chiesi Ventures has 9 tracked investments.
- What stage does Chiesi Ventures invest at?
- Chiesi Ventures invests at the Seed, Series A stages.
- What is Chiesi Ventures's typical check size?
- Chiesi Ventures typically writes checks of $5M.
- What sectors does Chiesi Ventures focus on?
- Chiesi Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Chiesi Ventures located?
- Chiesi Ventures is headquartered in Boston, US.
- Does Chiesi Ventures lead rounds?
- Yes, Chiesi Ventures leads investment rounds.
- Who does Chiesi Ventures co-invest with?
- Chiesi Ventures most often shares deals with Advent Life Sciences, RiverVest Venture Partners, Ysios Capital, among 24 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.